Cell Therapeutics out to raise $40M

Cell Therapeutics is looking to raise around $40 million through the sale of stock as it seeks an FDA approval on its latest cancer therapy. Xconomy notes the Seattle-based company has raised $1.3 billion over 18 years without consistently turning a profit. Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.